Core Viewpoint - SOPHiA GENETICS reported strong preliminary financial results for Q4 and full year 2025, with expectations of 20-22% revenue growth in 2026 and announced an executive transition plan promoting Ross Muken to CEO effective July 1, 2026 [1][2][3] Financial Performance - Q4 2025 revenue is projected to be at least $21 million, reflecting a year-over-year increase of approximately 20% [6] - The company performed over 105,000 analyses on SOPHiA DDM™ in Q4 2025, marking a 16% year-over-year growth [6] - Full year 2025 revenue is approximately $77 million, representing an 18% year-over-year increase [6] - The total revenue for 2026 is guided to be between $92 million and $94 million, indicating a year-over-year growth of approximately 20% to 22% [7] Executive Transition - Ross Muken, currently President and a key executive for five years, will succeed Jurgi Camblong as CEO [3][5] - Jurgi Camblong will transition to Executive Chairman, focusing on strategic initiatives and technology innovation [4][5] - Kevin Puylaert has been appointed Chief Sales Officer effective January 2026, bringing over 10 years of experience with the company [10] Growth Catalysts - The company anticipates growth drivers in 2026, including advancements in its Liquid Biopsy application MSK-ACCESS powered by SOPHiA DDM™, opportunities in the U.S. market, and a revitalized BioPharma business [2]

Core Insights - Several biotechnology and life sciences companies experienced significant gains in after-hours trading, indicating strong investor interest in recent clinical and corporate developments [1] Company Summaries - Kura Oncology, Inc. (KURA) saw its shares rise to $10.57, an increase of 7.42% (+0.73), likely due to positive investor sentiment following the announcement of new data from its KOMET-007 Phase 1a/1b trial, which showed a favorable safety profile and encouraging antileukemic activity for its treatment regimen in acute myeloid leukemia patients [2] - SOPHiA GENETICS SA (SOPH) closed after hours at $4.85, gaining 5.21% (+0.24), with continued investor interest stemming from its collaboration with Complete Genomics to co-market precision oncology testing solutions [3] - Elutia Inc. (ELUT) experienced modest gains, with shares rising to $0.6045, up 3.10% (+0.0182), reflecting steady investor interest in the micro-cap biotech sector [4] - RenovoRx, Inc. (RNXT) added 2.47% (+0.02) to close at $0.9530, with recent news of its abstract submission acceptance for the ASCO Gastrointestinal Cancers Symposium 2026, where it will present findings from its ongoing Phase III trial [5] - Kodiak Sciences Inc. (KOD) posted a notable gain, climbing to $27.41, up 5.42% (+1.41), following the successful closing of a public offering that generated approximately $184 million in gross proceeds [6] - Day One Biopharmaceuticals, Inc. (DAWN) rose to $9.55, gaining 3.35% (+0.31), continuing to attract investor attention focused on oncology innovation [7] - Quantum BioPharma Ltd. (QNTM) advanced to $9.23, up 3.82% (+0.34), following the closing of a non-brokered private placement that raised gross proceeds of $750 [8]

Core Insights - Azenta and SOPHiA GENETICS are compared based on various financial metrics and market performance indicators to determine which company is superior in the medical sector Volatility and Risk - Azenta has a beta of 1.29, indicating its share price is 29% more volatile than the S&P 500 - SOPHiA GENETICS has a beta of 1.1, suggesting its share price is 10% more volatile than the S&P 500 [1][2] Institutional & Insider Ownership - 99.1% of Azenta shares are owned by institutional investors, while 31.6% of SOPHiA GENETICS shares are owned by institutional investors - 10.6% of Azenta shares are owned by company insiders, compared to 4.9% for SOPHiA GENETICS [2] Profitability - Azenta's net margin is -10.01%, return on equity is 1.40%, and return on assets is 1.17% - SOPHiA GENETICS has a net margin of -41.13%, return on equity of -37.75%, and return on assets of -18.75% [4] Earnings and Valuation - Azenta's gross revenue is $593.82 million with a price/sales ratio of 2.71, while SOPHiA GENETICS has a gross revenue of $65.17 million and a price/sales ratio of 5.03 - Azenta's net income is -$59.50 million with an earnings per share of -$1.30 and a price/earnings ratio of -26.96 - SOPHiA GENETICS has a net income of -$62.49 million with an earnings per share of -$0.46 and a price/earnings ratio of -10.54 - Azenta has higher revenue and earnings than SOPHiA GENETICS and is trading at a lower price-to-earnings ratio, indicating it is more affordable [6] Analyst Recommendations - Azenta has 2 sell ratings, 3 hold ratings, and 3 buy ratings, resulting in a rating score of 2.13 - SOPHiA GENETICS has 1 sell rating, 0 hold ratings, and 2 buy ratings, resulting in a rating score of 2.33 - Azenta's consensus price target is $38.60, suggesting a potential upside of 10.13%, while SOPHiA GENETICS has a consensus price target of $9.00, suggesting a potential upside of 85.57% [8] Summary - Azenta outperforms SOPHiA GENETICS in 9 out of 14 factors compared between the two companies [9]

Core Insights - Complete Genomics and SOPHiA GENETICS have announced a collaboration to co-market MSK-ACCESS® and MSK-IMPACT® powered by SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform, aiming to enhance access to precision oncology testing globally [1][2]. Group 1: Collaboration Details - The partnership integrates SOPHiA GENETICS' AI-powered applications with Complete Genomics' DNBSEQ-T1+ platform, providing a sample-to-report workflow for laboratories [2]. - This collaboration marks a significant expansion into the precision oncology research market, enhancing the capabilities of both companies [2][3]. Group 2: Technology and Performance - The DNBSEQ-T1+ platform offers Q40-level accuracy and optimized throughput ranging from 500 million to 2 billion reads per flow cell, with a 24-hour paired-end 150bp run time [3]. - Each flow cell can run up to 60 tumor-normal sample pairs for tissue and up to 16 for liquid biopsy, providing a cost-effective and flexible sequencing solution [3]. Group 3: Benefits and Impact - The collaboration aims to enable decentralized labs to deliver faster, more accurate, and affordable insights to clinicians and researchers [3]. - SOPHiA DDM™ is a technology-agnostic analytics platform that enhances the analysis of healthcare data, demonstrating lower background noise and reduced turnaround time compared to other systems [4]. Group 4: Market Positioning - This new offering provides clinical laboratories, cancer centers, and drug developers with a high-performance, cost-efficient path for implementing comprehensive genomic profiling in precision oncology research [5]. - The collaboration is positioned to broaden access to data-driven medicine, allowing more laboratories worldwide to adopt precision oncology solutions [3][4].

Core Insights - SOPHiA GENETICS and Element Biosciences announced a partnership to integrate sequencing and AI analytics, aiming to enhance genomic workflows and support precision medicine research [1][2][4] Company Overview - SOPHiA GENETICS is a leader in AI-driven precision medicine, focusing on expanding access to data-driven healthcare through its SOPHiA DDM™ platform [8] - Element Biosciences is transforming scientific discovery with advanced technologies that enhance the pace and accessibility of genomics [9] Partnership Details - The collaboration combines SOPHiA DDM™ with Element's AVITI24™ 5D multiomic and AVITI sequencing systems, creating a streamlined end-to-end workflow for next-generation sequencing (NGS) [2] - This integration is expected to provide speed, scalability, and flexibility, allowing clinical researchers to derive actionable insights from NGS data efficiently [2][4] Expected Impact - The partnership aims to democratize access to genomic research, enabling healthcare organizations of all sizes to adopt innovative, AI-driven technologies [4] - The collaboration is anticipated to enhance the accuracy and consistency of genomic testing, ultimately accelerating the delivery of precision medicine to more patients [3][4]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $19.5 million, a 23% increase from $15.9 million in Q3 2024, continuing a trend of accelerating growth [26][32] - Adjusted gross margin remained flat at 73.1% year-over-year, despite a 40% increase in data processed by the platform [12][28] - Adjusted EBITDA loss was $10.2 million, an 8% increase from the prior year loss of $9.4 million, indicating improved operating leverage when excluding certain charges [31][33] Business Line Data and Key Metrics Changes - The company signed 31 new customers in Q3, bringing the total for 2025 to 94, surpassing the 92 customers signed in all of 2024 [5][18] - Revenue from the US market grew 30% year-over-year, contributing significantly to overall growth [7][15] - HMONK analysis volumes grew 18% year-over-year, while liquid biopsy testing saw over 2,000 analyses conducted in Q3, marking a 300% increase year-over-year [16][26] Market Data and Key Metrics Changes - EMEA region experienced a 24% revenue growth, with the UK and Belgium growing 120% and 70% respectively [15] - Asia-Pacific saw a 35% increase in analysis volume, with Japan beginning to contribute revenue as partnerships ramp up [16][19] - Latin America showed softness, but recent booking momentum suggests potential for recovery [16] Company Strategy and Development Direction - The company is focused on expanding its customer base and increasing the adoption of its applications, particularly in the US and liquid biopsy markets [5][10] - Strategic partnerships, such as with AstraZeneca for liquid biopsy testing, are expected to enhance market access and drive future growth [10][20] - The introduction of SOPHiA DDM Digital Twins aims to leverage multimodal data for better treatment decisions, indicating a shift towards more advanced AI-driven solutions [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's momentum, citing strong customer signings and a healthy pipeline for future growth [36] - The company raised its 2025 revenue guidance to $75 million-$77 million, reflecting optimism about continued growth [32][33] - Management acknowledged challenges such as elevated social charges and foreign exchange impacts but emphasized ongoing efforts to optimize costs and maintain growth [30][33] Other Important Information - The company analyzed over 99,000 patients across 70 countries in Q3, showcasing the extensive use of its platform [12] - Total cash burn for Q3 was $13.1 million, a 36.5% increase year-over-year, but the company maintains a strong cash position of $81.6 million [31][32] Q&A Session Summary Question: Why is the Q4 growth guidance lower than Q3? - Management indicated a conservative approach to guidance, emphasizing strong momentum but wanting to ensure continued overachievement [39][41] Question: How many liquid biopsy customers are generating revenue? - Approximately 20% of the 60 liquid biopsy customers have started routine analyses, with expectations for significant ramp-up in the coming quarters [42][45] Question: What is the outlook for biopharma R&D spending in 2026? - Management expressed optimism about biopharma spending, noting a favorable position for SOPHiA in the market and strong pipeline activity [50][53] Question: How did customer onboarding times trend in Q3? - Implementation activities remained healthy, with a substantial backlog still present, indicating strong future revenue potential [74] Question: What is the expected contribution from AstraZeneca in Q4? - AstraZeneca's contributions are expected to ramp up in Q4, with revenue recognized upon hitting project milestones [60][62]

Company Overview and Platform - SOPHiA GENETICS' AI platform SOPHiA DDM™ is used by over 800 healthcare institutions globally[7] - The platform analyzes over 350,000 patients per year[8, 21] and has analyzed over 2 million profiles since its inception[8] - The company has invested over $400 million since its inception to develop AI Factories and proprietary algorithms[21, 53] Market Trends and Data Analysis - Healthcare data accounts for 30% of all data generated globally[16] - In Q3 2025, SOPHiA GENETICS analyzed over 99,000 genomic analyses[31] - Total data processed on SOPHiA DDM™ has seen compounded growth of over 50% since 2021[38] Financial Performance and Outlook - The company's revenue for 2024 was $65.2 million[56] - Revenue is expected to be in the range of $75 million to $77 million in 2025, representing year-over-year growth of 15% to 18%[59] - Adjusted gross margin was 72.8% in 2024[59] and 73.1% in Q3 2025[63] - The company has a cash balance of $81.6 million as of Q3 2025[63]

Core Insights - SOPHiA GENETICS reported a strong third quarter for 2025, with revenue growth accelerating to 23% year-over-year, marking the third consecutive quarter of growth [3][6] - The company signed 31 new customers in Q3 2025, with an average contract value increase of 180% year-over-year, indicating robust business momentum [3][7] - The adjusted EBITDA loss improved by 13% year-over-year when excluding elevated Swiss social charges on equity-based compensation, reflecting strong operational leverage [3][12] Financial Performance - Revenue for Q3 2025 was $19.5 million, up from $15.9 million in Q3 2024, representing a 23% increase [6][32] - Gross margin was reported at 66.3% and adjusted gross margin at 73.1%, compared to 67.2% and 73.1% respectively in the prior year [6][33] - The net IFRS loss was $20.0 million, a 9% increase from the previous year, while the adjusted EBITDA loss was $10.2 million, up 8% year-over-year [6][30] Business Highlights - The company performed a record 99,000 analyses on its SOPHiA DDM platform, achieving a 9% year-over-year volume growth [7] - Significant growth was noted in the U.S. market, with a 30% year-over-year revenue increase [12] - SOPHiA DDM was adopted by major institutions, including Nice University Hospital in France and Baylor Scott & White Health in Texas, expanding its application areas [7][12] Future Outlook - Full-year revenue is now expected to be between $75 million and $77 million, reflecting a year-over-year growth of 15% to 18% [6][12] - The adjusted EBITDA loss is projected to be between $39 million and $41 million for the full year, factoring in the impact of Swiss social charges and currency fluctuations [6][12] - The company aims to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027 [12][30]

Revenue and Profit - Revenue for Q3 2025 was $19,462 thousand, a 22% increase from $15,853 thousand in Q3 2024[5] - Gross profit for Q3 2025 reached $12,907 thousand, up from $10,654 thousand in Q3 2024, reflecting a 21% growth[5] - The revenue from the SOPHiA DDM Platform for the three months ended September 30, 2025, was $18.667 million, up from $15.584 million in 2024, representing a growth of 19%[45] Losses and Financial Position - Operating loss for the nine months ended September 30, 2025, was $52,390 thousand, compared to $49,124 thousand for the same period in 2024, indicating a 5% increase in losses[5] - Total comprehensive loss for Q3 2025 was $20,235 thousand, compared to $11,621 thousand in Q3 2024, representing a 74% increase in losses[7] - The accumulated deficit as of September 30, 2025, was $500,097 thousand, up from $440,277 thousand at the end of 2024, indicating a worsening financial position[10] - For the nine months ended September 30, 2025, the loss before tax was $57,913 thousand, compared to a loss of $46,728 thousand for the same period in 2024[13] - The net loss attributed to shareholders for the three months ended September 30, 2025, was $20.021 million, compared to a loss of $18.438 million in 2024[47] Cash and Liquidity - Cash and cash equivalents as of September 30, 2025, were $81,610 thousand, slightly up from $80,226 thousand at the end of 2024[9] - Cash used in operating activities for the nine months ended September 30, 2025, was $27,757 thousand, a decrease from $33,829 thousand in the prior year[13] - The net cash flow provided by financing activities for the nine months ended September 30, 2025, was $30,562 thousand, compared to $11,025 thousand in 2024[13] - As of September 30, 2025, cash and cash equivalents were $81,610 thousand, down from $95,787 thousand at the end of the previous year[13] Assets and Liabilities - Total assets increased to $163,458 thousand as of September 30, 2025, from $155,309 thousand at the end of 2024, marking a 5% growth[9] - Total liabilities rose to $102,771 thousand as of September 30, 2025, compared to $58,819 thousand at the end of 2024, reflecting a significant increase of 74%[9] Expenses - Research and development costs for Q3 2025 were $8,067 thousand, slightly higher than $7,874 thousand in Q3 2024[5] - Selling and marketing costs increased to $8,670 thousand in Q3 2025 from $7,306 thousand in Q3 2024, a rise of 18.7%[5] - The company reported share-based compensation of $12,337 thousand for the nine months ended September 30, 2025, compared to $11,410 thousand in the prior year[13] - The total interest expense recorded for the nine months ended September 30, 2025, was $2.486 million[60] - The Company reported share-based compensation expenses totaling $4.146 million for the three months ended September 30, 2025, compared to $3.613 million for the same period in 2024[62] Financing Activities - The Company drew down $35.0 million from the second tranche of term loans on June 25, 2025, under the Perceptive Credit Agreement[51] - The Company accounted for Tranche B of the term loans and warrants as two separate financial instruments, with a total drawdown of $35.0 million[52] - The Tranche A loan was recorded at an initial amortized cost of $13.3 million, while Tranche B was recorded at an initial amortized cost of $34.1 million[59] - The effective interest rate (EIR) for Tranche B was determined to be 12.4% upon initial drawdown[56] - The fair value of the Tranche A warrant obligation was initially measured at $0.7 million, and for Tranche B at $0.5 million[57] - As of September 30, 2025, the Company had no borrowings outstanding under the new credit facility with Credit Suisse SA[61] Other Financial Information - The Company signed a stock purchase agreement to acquire a minority equity interest in A.D.A.M. Innovations for a total of $2.0 million, with $0.5 million acquired in September 2025 and $1.5 million in October 2025[41] - The Company completed its purchase of shares in A.D.A.M. Innovations for $1.5 million in October 2025[66] - The Company entered into a 73-month lease for office space in Boston, Massachusetts, with a right-of-use asset recorded at $2.0 million[48] - The Company’s accounts receivable as of September 30, 2025, amounted to $8.455 million, an increase from $7.436 million as of December 31, 2024[46] - The allowance for expected credit losses decreased to $345,000 as of September 30, 2025, from $394,000 as of December 31, 2024[46] - The Company’s largest customer represented 9% of accounts receivable as of September 30, 2025, down from 18% as of December 31, 2024[46] - Key management personnel compensation for the nine months ended September 30, 2025, totaled $11.103 million, compared to $13.788 million for the same period in 2024[65] Accounting Changes - The company reclassified interest paid from operating activities to financing activities, and interest received from operating activities to investing activities effective January 1, 2025[24] - The company is currently evaluating the impact of IFRS 18, effective January 1, 2027, on its financial statements[30]

Core Insights - A.D.A.M. Innovations and SOPHiA GENETICS have formed a strategic partnership to introduce advanced liquid biopsy genomic testing in Japan, aiming to enhance personalized cancer care [1][4][5] - The collaboration will leverage SOPHiA's AI-powered DDM Platform to improve cancer testing efficiency and accuracy, with a focus on local testing and research [2][3][5] Company Overview - A.D.A.M. Innovations has been a leader in genetic testing in Japan for over 20 years, having conducted more than 2.8 million genomic tests [2][9] - SOPHiA GENETICS is a cloud-native healthcare technology company specializing in AI-driven data analysis for cancer and rare disorders [6] Partnership Details - The initial focus will be on launching the MSK-ACCESS® liquid biopsy application, which detects genomic alterations from a single blood draw using AI to analyze circulating tumor DNA [3][4] - The companies plan to develop a liquid biopsy companion diagnostic test to enhance access to tumor profiling and support drug development in Japan [4][5] Strategic Goals - The partnership aims to make precision oncology more accessible in Japan, combining local expertise with global technology to drive the adoption of data-driven medicine [5] - A.D.A.M. Innovations will utilize its clinical and regulatory knowledge to facilitate the development and approval processes for new diagnostic tools [4][5]